growth driver is primarily the liquid medicine division Kabi. As the company from Bad Homburg announced late Monday, is expected to grow currency-adjusted by 11 to 14 percent in the current year, adjusted for special items surplus. Previously, Fresenius had planned an increase of 8 to 12 percent. The previous sales forecast – an increase of 6 to 8 percent – remains
Investors were given the news pleased: The share price of Fresenius ended OTC trading at Lang & amp;. Black at a premium of just under two percent.
BETTER THAN EXPECTED BUSINESS AT KABI
The division Kabi, in the Fresenius business with infusions, liquid generic and clinical nutrition bundles, to both organic sales and operating profit to grow by 3 to 5 percent. Previously, the company had run out of a low single-digit organic sales growth and operating profit from the previous year. But the second quarter was now, partly because of the strong performance in North America, better than expected. The second half of the year offers good prospects for the region as well as in the emerging markets, it said at Fresenius. For the other sectors, the dialysis subsidiary Fresenius Medical Care (FMC), the hospital operator Helios and the project company Vamed Fresenius confirmed meanwhile predictions.
In the second quarter, Fresenius increased sales by 2 percent to 7.1 billion euros , negative currency effects reduced. The adjusted for special items earnings before interest and taxes (EBIT) rose meanwhile by 8 percent to 1.05 billion euros. Adjusted for extraordinary impacts and currency effects result after minorities was 12 percent higher at 393 million euros. Analysts had, however, expected to be slightly better turnover with less profit.
FMC EXCEEDS EXPECTATIONS OF EXPERTS
The dialysis specialist FMC, which is also listed on the DAX and in US dollars accounted, grew partly thanks to improvements in North America in the second quarter. Revenue rose 5 percent to 4.42 billion dollars. In addition, FMC recorded cost savings. So climbed adjusted for special items earnings before interest and taxes (EBIT) by 17 percent to € 641 million after above. Adjusted net income rose 22 percent to 294 million dollars.
This surpassed the world’s largest provider of dialysis equipment and materials analysts’ expectations in the operating result and the surplus. The previous forecast was made: It is expected currency-adjusted sales growth of 7 to 10 percent and earnings growth of between 15 and 20 percent. The price of the FMC shares gained after trading almost one percent.
No comments:
Post a Comment